Silexion Therapeutics Corp (SLXN)
| Market Cap | 1.47M -30.0% |
| Revenue (ttm) | n/a |
| Net Income | -13.96M |
| EPS | -38.75 |
| Shares Out | 5.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,555,466 |
| Open | 0.2689 |
| Previous Close | 0.3153 |
| Day's Range | 0.2500 - 0.2806 |
| 52-Week Range | 0.2551 - 42.6000 |
| Beta | -0.36 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 11, 2026 |
About SLXN
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre... [Read more]
Financial Performance
Financial StatementsNews
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
Grand Cayman, Cayman Islands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interfe...
Silexion Therapeutics prices $2.5M public offering at $0.65 per share
Silexion Therapeutics (SLXN) announced the pricing of a public offering of an aggregate of 3,846,161 of the Company’s ordinary shares and series E warrants to purchase up to 3,846,161 ordinary…
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center ...
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering...
Silexion Therapeutics files to sell ordinary shares, warrants, no amount given
16:40 EDT Silexion Therapeutics (SLXN) files to sell ordinary shares, warrants, no amount given
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers Silexion to present SIL-204 data at leading Cancer Symposium designed to ...
Silexion Therapeutics downgraded at Maxim on delisting and dilution risk
As previously reported, Maxim downgraded Silexion Therapeutics (SLXN) to Hold from Buy and removed the firm’s prior price target Due to the recent change in Nasdaq listing rules, as well…
Silexion Therapeutics downgraded to Hold from Buy at Maxim
Maxim analyst Naz Rahman downgraded Silexion Therapeutics (SLXN) to Hold from Buy.
Silexion Therapeutics initiates SIL204 trial
Silexion Therapeutics (SLXN) announced the initiation of its Phase 2/3 clinical trial of SIL204, the company’s small interfering RNA product candidate, at Tel Aviv Sourasky Medical Center, formally ac...
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
Successful initiation of the Phase 2/3 clinical trial of SIL204 at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), one of Israel's largest and most prominent academic medical centers, clears ...
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion...
Silexion Therapeutics to Attend BIO International Convention 2026
Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-...
Silexion Therapeutics files to sell 859,609 ordinary shares for holders
16:08 EDT Silexion Therapeutics (SLXN) files to sell 859,609 ordinary shares for holders
Silexion Therapeutics Corp trading halted, news pending
19:50 EDT Silexion Therapeutics (SLXN) Corp trading halted, news pending
Silexion Therapeutics announces 1-for-10 reverse share split
Silexion Therapeutics (SLXN) announced a 1-for-10 reverse share split of its ordinary shares. The reverse share split will become effective after market close on May 28, 2026, and the Company’s…
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expected to help Silexion comply with Nasdaq requirements, enhance its market position, and support its pr...
3 Penny Stocks to Watch Now, 5/21/26
HCW Biologics ($HCWB), MetaVia ($MTVA), and Silexion Therapeutics ($SLXN) are the three penny stocks to watch on May 21, according to TipRanks’ Penny Stock Screener tool. Penny stocks refer to low-pri...
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) thera...
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following SIL204 treatment in human pancreatic and non-small cell lung cancer cells har...
Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204
Silexion Therapeutics (SLXN) announced the initiation of good manufacturing practice, or GMP, clinical batch manufacturing of SIL204, the company’s siRNA therapy targeting mutated KRAS, in support of ...
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its Europe...
Silexion Therapeutics submits SIL204 clinical trial application to Germany
Silexion Therapeutics (SLXN) announced the recent successful submission of a clinical trial application, or CTA, to Germany for its planned Phase 2/3 clinical trial of its lead, small interfering RNA…
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program CTA submission positions Si...
Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204
Silexion Therapeutics (SLXN) announced that it has received formal approval from the Israeli Ministry of Health to initiate its Phase 2/3 clinical trial evaluating SIL204 for the treatment of locally…